To determine if an alternating regimen of imatinib and regorafenib has sufficient activity and safety to warrant further evaluation as a first line treatment for metastatic GIST.
NHMRC CTC; EORTC; SSG
Adults with histologically confirmed, measurable metastatic GIST, who have received no prior treatment for metastatic disease. Patients who are currently taking, and have had up to 21 days of uninterrupted treatment with 400mg daily of imatinib are eligible to participate in this study.
ACTRN12614000950662 & NCT02365441
Australian Lead Group:
Desmond Yip (ANZ Study Chair), Heikke Joensuu (International Study Chair)